Aurora Cannabis Reports Record Annual Medical Revenue & EBITDA, but Forecasts FY27 Revenue Decline and Lower EBITDA
ACB is trading near its 52-week low of $2.73 (6.8% above the low) on elevated volume (2.0× avg).
Summary
Aurora Cannabis announced record annual medical cannabis revenue and adjusted EBITDA for FY26, but its Q4 results were mixed, and the company issued a negative outlook for FY27, forecasting declining revenue and lower EBITDA.
Key Events · Earnings and Guidance · ACB
-
Record Annual Performance
Achieved record annual global medical cannabis net revenue of $288.6 million (18% YoY growth) and record annual Adjusted EBITDA of $53.8 million (32% YoY growth) for fiscal year 2026.
-
Mixed Q4 Financials
Reported Q4 total net revenue of $84.8 million (10% YoY increase) driven by medical cannabis, but Adjusted EBITDA declined to $9.2 million from $14.1 million YoY, and free cash flow was $0.3 million, down from $5.2 million YoY.
-
Negative FY27 Outlook
Forecasts a decline in total net revenue for fiscal year 2027, aligning with FY25 levels, and expects lower annual Adjusted EBITDA compared to the prior fiscal year due to changes in Canadian medical pricing.
-
Strong Cash Position
Maintains a strong balance sheet with approximately $164.7 million in cash, short-term investments, and cash equivalents, with no debt.
Analysis · ACB · Life Sciences
Aurora Cannabis reported record annual global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, demonstrating strong performance in its core medical segment. However, the fourth quarter saw a decline in adjusted EBITDA and free cash flow, and more critically, the company provided a negative outlook for fiscal year 2027, projecting a decline in total net revenue and lower annual adjusted EBITDA. This forward guidance suggests a challenging year ahead despite past successes, which is a significant market-moving signal.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.3M. The 52-week trading range was $2.73 to $6.67. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.